GlaxoSmithKline

GlaxoSmithKline logo
🇬🇧United Kingdom
Ownership
Public
Established
1929-01-01
Employees
70.2K
Market Cap
$90B
Website
http://www.gsk.com
Introduction

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general med...

A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above

First Posted Date
2022-09-29
Last Posted Date
2024-04-04
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
1029
Registration Number
NCT05559476
Locations
🇺🇸

GSK Investigational Site, San Antonio, Texas, United States

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1

Phase 2
Completed
Conditions
Interventions
First Posted Date
2022-09-23
Last Posted Date
2023-01-19
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
105
Registration Number
NCT05553808
Locations
🇸🇪

GSK Investigational Site, Uppsala, Sweden

To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD

Phase 4
Completed
Conditions
Interventions
First Posted Date
2022-09-10
Last Posted Date
2024-11-04
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
463
Registration Number
NCT05535972
Locations
🇵🇱

GSK Investigational Site, Warszawa, Poland

A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age

First Posted Date
2022-08-11
Last Posted Date
2024-11-13
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
1080
Registration Number
NCT05496231
Locations
🇵🇱

GSK Investigational Site, Warszawa, Poland

Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old

First Posted Date
2022-07-28
Last Posted Date
2024-03-01
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
180
Registration Number
NCT05477186
Locations
🇺🇸

Optimal Research Florida - Melbourne, Melbourne, Florida, United States

🇺🇸

Research Centers of America - CenExcel, Hollywood, Florida, United States

🇺🇸

Optimal Research Illinois - Peoria, Peoria, Illinois, United States

and more 19 locations

Linerixibat Compassionate Use for Cholestatic Pruritus Adult Patients With Primary Biliary Cholangitis (PBC)

Conditions
First Posted Date
2022-07-07
Last Posted Date
2023-11-08
Lead Sponsor
GlaxoSmithKline
Registration Number
NCT05448170

Food Effect Study of Linerixibat Tablets in Healthy Adult Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2022-06-28
Last Posted Date
2022-11-29
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
23
Registration Number
NCT05435170
Locations
🇬🇧

GSK Investigational Site, Cambridge, United Kingdom

A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS

Phase 1
Terminated
Conditions
Interventions
First Posted Date
2022-06-21
Last Posted Date
2024-09-27
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
18
Registration Number
NCT05424380
Locations
🇪🇸

GSK Investigational Site, Valencia, Spain

© Copyright 2024. All Rights Reserved by MedPath